The glycopeptide vancomycin does not enhance toll-like receptor 2 (TLR2) activation by Streptococcus pneumoniae | Zendy

L.J. Moore | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The glycopeptide vancomycin does not enhance toll-like receptor 2 (TLR2) activation by Streptococcus pneumoniae

Author(s) -

L.J. Moore

Publication year - 2004

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkh301

Subject(s) - streptococcus pneumoniae , microbiology and biotechnology , cefotaxime , tlr2 , cd14 , biology , vancomycin , antibacterial agent , antibiotics , bacteria , tlr4 , immunology , staphylococcus aureus , immune system , flow cytometry , genetics

The exposure of Streptococcus pneumoniae to cell-wall-active antibiotics in vivo and in vitro results in the release of bacterial components that can induce proinflammatory activation of human cells via toll-like receptor 2 (TLR2). The aim of this study was to compare the activation of human TLR2 pathways after exposure of S. pneumoniae to faropenem, cefotaxime and vancomycin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research